The Cost-effectiveness of a Flash Glucose Monitoring System for Management of Patients with Type 2 Diabetes Receiving Intensive Insulin Treatment in Sweden
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Flash glucose monitoring, an alternative to traditional self-monitoring of blood glucose (SMBG), prevents hypoglycaemic events without impacting glycated haemoglobin (REPLACE trial). Given the potential benefits, this study assessed the cost-effectiveness of using flash monitoring versus SMBG alone in patients with type 2 diabetes (T2D) receiving intensive insulin treatment in Sweden. Methods: This study used the IQVIA CORE Diabetes Model (IQVIA CDM, v8.5) to simulate the impact of flash monitoring versus SMBG over 40 years from the Swedish societal perspective. Baseline characteristics, intervention effects, and resource utilisation were derived from REPLACE; literature and Tandvårds-Läkemedelförmånsverket (TLV) sources informed utilities and costs. Scenario analyses explored the effect of key base case assumptions. Results: In base case analysis, direct medical costs for flash monitoring use were SEK1,630,586 (158,523) versus SEK1,459,394 (141,902) for SMBG use. Flash monitoring led to 0.56 additional quality-adjusted life years (QALYs; 6.21 versus 5.65 SMBG) for an incremental cost-effectiveness ratio (ICER) of SEK306,082/QALY (29,762/QALY). ICERs for all scenarios remained under SEK400,000/QALY (38,894/QALY). Conclusions: Hypoglycaemia and health utility benefits due to flash glucose monitoring may translate into economic value compared to SMBG. With robust results across scenario analyses, flash monitoring may be considered cost-effective in a Swedish population of T2D intensive insulin users.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mechanisms of Diabetic Complications
Forbes, J. M., & Cooper, M. E. (2013) · Physiological Reviews · doi:10.1152/physrev.00045.2011 · Cited by 2,890 · cited 1×
“Moreover, patients with diabetes are at higher risk for disabling or life-threatening health problems than non-diabetic patients.(5)”
BackgroundO'Connor (2009) · doi:10.1001/jama.2009.454 · Cited by 2,173
Epidemiology of type 1 diabetes
Maahs, D. M., West, N. A., Lawrence, J. M., & Mayer-Davis, E. J. (2010) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2010.05.011 · Cited by 1,092
Hex, N., Bartlett, C., Wright, D., Taylor, M., & Varley, D. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03698.x · Cited by 819
Epidemiology of severe hypoglycemia in the diabetes control and complications trial
(1991) · The American Journal of Medicine · doi:10.1016/0002-9343(91)80085-z · Cited by 807
Epidemiology of severe hypoglycemia in the Diabetes Control and Complications Trial
(1991) · The American Journal of Medicine · doi:10.1016/0002-9343(91)90605-w · Cited by 807
Haak, T., Hanaire, H., Ajjan, R., Hermanns, N., Riveline, J.-P., & Rayman, G. (2017) · Diabetes Therapy · doi:10.1007/s13300-016-0223-6 · Cited by 623 · cited 2×
“7% reduction in measured hypoglycaemia <70 mg/dl for flash monitoring compared to SMBG, without raising HbA1c levels.(26)”
MethodHayes, A. J., Leal, J., Gray, A. M., Holman, R. R., & Clarke, P. M. (2013) · Diabetologia · doi:10.1007/s00125-013-2940-y · Cited by 495
Goto, A., Arah, O. A., Goto, M., Terauchi, Y., & Noda, M. (2013) · BMJ · doi:10.1136/bmj.f4533 · Cited by 492 · cited 1×
“However, recent evidence has suggested that people experiencing hypoglycaemic events may be at an increased risk of cardiovascular disease.(59,60) Although the baseline characteristics in that study may differ from our analysis, it raises the possibility that our analysis underestimates the value of reducing hypoglyca…”
BackgroundContinuous glucose monitoring systems for type 1 diabetes mellitus
Langendam, M., Luijf, Y. M., Hooft, L., DeVries, J. H., Mudde, A. H., & Scholten, R. J. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008101.pub2 · Cited by 262
Cited by
Continuous glucose monitoring for the routine care of type 2 diabetes mellitus
Ajjan, R. A., Battelino, T., Cos, X., Del Prato, S., Philips, J.-C., Meyer, L., Seufert, J., & Seidu, S. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-00973-1 · Cited by 117
“Four studies across a range of health-care economies have found that the use of isCGM in people with T2DM on MDI or CSII therapy is considered cost-effective compared with standard care with SMBG, based on a 40-year horizon 137,138,170,171 .”
Ajjan, R., Bilir, S. P., Hellmund, R., & Souto, D. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01325-w · Cited by 14
Self-citationHarris, S., Cimino, S., Nguyen, Y., Szafranski, K., & Poon, Y. (2025) · Diabetes Therapy · doi:10.1007/s13300-024-01677-5 · Cited by 12
“Several additional studies have found Free-Style Libre to be cost-effective in other countries, including analyses of persons living with T1DM or T2DM using MDI in the UK and Sweden [35, 73–75].”
Al Hayek, A. A., & Al Dawish, M. A. (2023) · Advances in Therapy · doi:10.1007/s12325-023-02508-y · Cited by 9
Metadata
- Authors
- Bilir, S. P., Hellmund, R., Wehler, E., Li, H., Munakata, J., & Lamotte, M.
- Venue
- European Endocrinology
- Publisher
- Touch Medical Media, Ltd.
- Published
- 2018
- Volume
- 14
- Issue
- 2
- Pages
- 80
- ISSN
- 1758-3772 (ISSN-L)
- OpenAlex
- W2889659549
- Cited by
- 23
- References
- 14
- FWCI
- 1.88
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Cost-effectiveness of a Flash Glucose Monitoring System for Management of Patients with Type 2 Diabetes Receiving Intensive Insulin Treatment in Sweden. https://app.cochat.ai/papers/10.17925/ee.2018.14.2.80
- The paper
- Bilir, S. P., Hellmund, R., Wehler, E., Li, H., Munakata, J., & Lamotte, M. (2018). The Cost-effectiveness of a Flash Glucose Monitoring System for Management of Patients with Type 2 Diabetes Receiving Intensive Insulin Treatment in Sweden. European Endocrinology. https://doi.org/10.17925/ee.2018.14.2.80
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.